Aurora Cannabis Launches Three New Flower Strains in New Zealand and Four 780mg/g THC Cartridges in Australia
Aurora Cannabis expanded its medical portfolio in New Zealand with the launches of Big Wave (26% THC), Night Ride (29% THC) and Half Moon (9% THC, 13% CBD) due by Q1 FY27. In Australia, it introduced four 780 mg/g THC resin cartridges—Chemango Kush, Cosmic Cream, Lunar Express, Soul Train Haze.
1. Product Launch in New Zealand and Australia
Aurora Cannabis rolled out Big Wave (THC 26%, CBD <1%), Night Ride (THC 29%, CBD <1%) and plans to introduce Half Moon (THC 9%, CBD 13%) in New Zealand by Q1 FY27. In Australia, it launched four resin cartridges—Chemango Kush, Cosmic Cream, Lunar Express and Soul Train Haze—each containing 780 mg/g THC.
2. Market Significance and Strategy
This expansion targets two of Aurora’s largest international medical markets, reinforcing its strategy to drive long-term revenue growth through diversified, high-margin product formats. By broadening its portfolio, the company aims to increase prescriptions and patient access across key regions, leveraging its established regulatory expertise and distribution networks.
3. Quality Assurance and Manufacturing
All new products are produced using Aurora’s proprietary genetics and manufactured at its EU-GMP and TGA-GMP certified facilities in Canada. These certifications ensure compliance with rigorous quality and safety standards, supporting Aurora’s commitment to reliable product supply and consistent patient experience.